Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales drop

This article was originally published in The Tan Sheet

Executive Summary

Mannatech reports a loss of $3.6 million for its fiscal 2007 fourth quarter due to declining sales and $4.7 million in litigation expenses. In August, co-founder and CEO Sam Caster resigned amid Mannatech's defense of the class action (1"The Tan Sheet" Aug. 27, 2007, In Brief). Sales for the October-December period fell 6.5 percent to $99.9 million from $106.8 million. The firm says North American sales dropped 20 percent, but international sales rose 27 percent. In a March 14 release, President and CEO Terry Persinger said the firm will focus on global business development and cost management and expects better results in the later part of the year...

You may also be interested in...



Mannatech CEO quits

Sam Caster, co-founder of Coppell, Texas-based multilevel dietary supplements marketer Mannatech, resigns as the firm's chief executive Aug. 21 amidst litigation charging the company engaged in deceptive sales practices. Caster will retain his position as chairman of the board. President and COO Terry L. Persinger, who will retire from the company in June 2008, has been appointed interim president and CEO while Mannatech seeks a permanent replacement. Additionally, Exec VP-Global Operations Terence L. O'Day will assume responsibility as COO. The Texas attorney general filed a lawsuit in July seeking to shut down Mannatech, due to its alleged use of false claims in marketing. However, Mannatech has vowed to fight the suit (1"The Tan Sheet" July 16, 2007, p. 11)...

Interview: OurCrowd CEO Jon Medved On Israel’s Medtech “Boomtown”

With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Topics

UsernamePublicRestriction

Register

PS101488

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel